Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced that its President and CEO, Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific rationale for treating Alzheimer's disease as a multi-protein disorder, highlighting Annovis' approach of simultaneously targeting multiple neurotoxic proteins through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
This announcement is significant because it underscores a paradigm shift in Alzheimer's research—moving from targeting single proteins to addressing the disease as a complex, multi-protein condition. Current treatments often focus on one pathological hallmark, such as amyloid beta plaques, but many patients continue to decline, suggesting that other proteins like tau, alpha-synuclein, and TDP-43 also play crucial roles. Annovis' buntanetap is designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing these underlying causes simultaneously, the company aims to halt disease progression and improve cognitive and motor functions in patients.
For the biotechnology industry, this presentation at a major conference like Fierce Biotech Week signals growing interest in multi-target therapies for neurodegenerative diseases. If buntanetap succeeds in its Phase 3 trial, it could set a new standard for Alzheimer's and Parkinson's treatment, potentially offering a more comprehensive approach than existing single-target drugs. The impact on patients could be profound, as slowing or halting the progression of these devastating diseases would improve quality of life and reduce the burden on healthcare systems.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins. The company's approach targets the underlying causes of neurodegeneration, aiming to stop disease progression rather than just manage symptoms.
For more information about Annovis Bio and buntanetap, visit the company's newsroom at https://ibn.fm/ANVS. The full press release is available at https://ibn.fm/kZ2Z4.
